Charcot-Marie-Tooth (CMT) – Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026

Charcot-Marie-Tooth (CMT) Emerging Therapy and TPP Insights

Thelansis’s “Charcot-Marie-Tooth (CMT) Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026″ provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication.

Charcot-Marie-Tooth (CMT) Overview

Charcot-Marie-Tooth disease (CMT) is the most common inherited peripheral neuropathy, encompassing a clinically and genetically heterogeneous group of disorders caused by mutations across numerous genes regulating peripheral nerve myelination and axonal integrity — most prevalently PMP22 duplication causing CMT1A, GJB1 mutations causing X-linked CMTX, and MPZ and MFN2 mutations underlying demyelinating and axonal subtypes respectively. The pathophysiology involves either primary Schwann cell and myelin dysfunction — producing demyelinating CMT1 subtypes with reduced nerve conduction velocities — or primary axonal degeneration in CMT2, with secondary myelin changes; both converge on progressive length-dependent peripheral motor and sensory neuronal loss. Patients present insidiously in childhood or early adulthood with distal lower limb weakness, foot deformity — pes cavus and hammer toes — steppage gait, sensory loss, and areflexia, with upper limb involvement and hand intrinsic wasting emerging as disease progresses. Diagnosis integrates nerve conduction studies delineating demyelinating versus axonal subtypes, alongside comprehensive genetic panel testing confirming causative mutations. No disease-modifying therapy currently exists; management is rehabilitative — physiotherapy, orthotic devices, and surgical correction of foot deformities optimise functional independence. Pain management addresses neuropathic symptoms, and respiratory monitoring is warranted in severe cases. Prognosis is generally favourable for ambulation maintenance; genetic counselling, multidisciplinary rehabilitation, and patient education regarding neurotoxic medication avoidance are integral to long-term patient-centred care.

Geography coverage:

G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)

Insights driven by surveys* with physician / key opinion leaders:

• Survey findings are corroborated and enriched by insights from interviews with leading KOLs

*Survey is customized based on client requirements

Deliverables format:

• PowerPoint presentation
• MS Excel

Key business questions answered:

• Detailed emerging competitive landscape
• Pipeline analysis
• Target patients for emerging therapies
• Key companies
• Key mechanism of actions
• Launch date estimates, etc.
• Clinical trial landscape analysis
• Target patient segments
• Trial endpoints
• Trial design
• Recruitment criteria, etc.
• Unmet Needs and Opportunities
• Performance of key current therapies
• Top areas of unmet needs
• Opportunity sizing for key unmet needs
• Target Product Profiles
• Attributes and levels
• Physician likelihood of prescribing
• Expected patient shares
• KOL insights on key emerging therapies
• Level of awareness
• Expected use / line of therapy
• Extent to fulfil key unmet needs
• KOL quotes

Read more: Charcot-Marie-Tooth (CMT) – Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026